Carbonyl iron-containing products side-effect data signify "need for caution," FDA says.
This article was originally published in The Tan Sheet
Executive Summary
CARBONYL IRON SIDE-EFFECT STUDIES SIGNIFY "NEED FOR CAUTION", FDA says, in evaluating "the limited evidence concerning the toxicity of carbonyl iron" in dietary supplements, the agency states in its denial of a Feb. 18 Rexall Sundown citizen petition concerning the Jan. 15 final rule on iron-containing drugs and supplements ("The Tan Sheet" Jan. 20, pp. 1-4). Rexall had sought both a reconsideration of the final rule and a stay of the warning label requirement for carbonyl iron-containing products ("The Tan Sheet" March 10, p. 9). Alternatively, Boca Raton, Fla.-based Rexall Sundown had requested a temporary exemption from the warning requirements.